CMA Recommendations on Vaccine Equity and Intellectual Property
https://policybase.cma.ca/link/policy14476

POLICY TYPE  Parliamentary submission
DATE  2022-05-13
TOPICS  Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents

CMA Recommendations on Vaccine Equity and Intellectual Property
House of Commons Standing Committee on Foreign Affairs and International Development
May 11, 2022
https://policybase.cma.ca/link/policy14443

POLICY TYPE
Policy endorsement

DATE
2021-06-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents


POLICY TYPE
Policy endorsement

DATE
2021-06-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Taking action on drug shortages during Covid-19 – open letter
https://policybase.cma.ca/link/policy14261

POLICY TYPE
Parliamentary submission

DATE
2020-08-13

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy11514

POLICY TYPE
Policy document

LAST REVIEWED
2020-02-29

DATE
2015-02-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE  Response to consultation
DATE  2019-05-24
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Cannabis for Medical Purposes
https://policybase.cma.ca/link/policy10045

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2010-12-04

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Cannabis for Medical Purposes

CMA POLICY

Policy Title:
The Canadian Medical Association (CMA) has long been recognized as a leader in the medical profession’s efforts to provide patients with the most effective and safe treatments available. However, the use of cannabis for medical purposes has been a controversial issue, with some debates围绕 its potential benefits and risks.

The CMA supports efforts to develop and implement policies that promote the safe and effective use of cannabis for medical purposes. The CMA recognizes the need for more research and evidence-based guidelines to inform clinical practice. The CMA encourages healthcare providers to remain informed about the latest developments in this area and to engage in ongoing professional development to ensure they are providing the best care possible to their patients.

The CMA encourages healthcare providers to:
1. Stay informed about the latest research and guidelines on the use of cannabis for medical purposes.
2. Discuss the potential benefits and risks of cannabis use with their patients.
3. Provide evidence-based guidance to patients on the safe and effective use of cannabis.
4. Encourage patients to discuss their cannabis use with their healthcare providers.

The CMA encourages healthcare providers to work with their colleagues and the community to promote the safe and effective use of cannabis for medical purposes.

Approved by the CMA Council on 2010-12-04
Medication use and seniors (Update 2017)
https://policybase.cma.ca/link/policy10151

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2011-05-28

REPLACES
Medication use and seniors

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA POLICY

MEDICATION USE AND SENIORS
(UPDATE 2017)

(Canadian Medical Association Policybase - Canadian Medical Association)

Copyright © Canadian Medical Association, all rights reserved.

Vision for e-Prescribing: a joint statement by the Canadian Medical Association, 2011-05-28

(Canadian Medical Association - Canadian Medical Association)

Copyright © Canadian Medical Association, all rights reserved.

[Image: CMA POLICY]

Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2012-12-08
TOPICS  Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2019-02-20</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
<tr>
<td></td>
<td>Population health, health equity, public health</td>
</tr>
</tbody>
</table>

Documents
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE         Response to consultation
DATE               2018-12-04
TOPICS             Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Implementation of National Pharmacare
https://policybase.cma.ca/link/policy13933

POLICY TYPE  Response to consultation
DATE          2018-10-02
TOPICS        Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

POLICY TYPE  Response to consultation
DATE  2018-09-06
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott

https://policybase.cma.ca/link/policy13931

POLICY TYPE  Policy endorsement
DATE  2018-08-30
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Policies

Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott

August 18, 2018
Re: Premier Ford and Premier Elliott

We, the undersigned physicians, call on your government to establish legal overdose prevention services and set conditions for harm reduction programs in order to save lives and reduce the number of drug-related deaths in our communities. We believe that these services would be a positive step towards ensuring that those who use illicit substances have access to medical treatment and care.

In our communities, we have witnessed the impact of drug addiction and overdose on individuals and families. We urge you to consider the following key points:

1. Establish legal overdose prevention services

   - These services will provide a safe and supervised environment for individuals to inject drugs, thereby reducing the risk of overdose.
   - Additionally, these services will provide access to naloxone and other emergency drugs to prevent deaths.

2. Legalize and regulate harm reduction programs

   - Legalizing harm reduction programs will reduce the stigma associated with drug use and provide access to necessary medical care.
   - Moreover, these programs will promote public health by addressing the root causes of addiction.

3. Support community-based programs

   - Community-based programs will provide ongoing support and reduce the burden on the healthcare system.
   - These programs will also promote social and mental health programs.

Consequently, we call on your government to act with urgency and consider the implementation of these services and programs in order to save lives and reduce the number of drug-related deaths in our communities.

Yours sincerely,
[Signatures]

[End of letter]
Health Canada consultation on regulatory amendments regarding tramadol
https://policybase.cma.ca/link/policy13927

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2018-08-14</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

**Documents**

CMA response:

HEALTH CANADA CONSULTATION ON REGULATORY AMENDMENTS REGARDING TRAMADOL

August 14, 2018
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

POLICY TYPE  Response to consultation
DATE  2018-07-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

POLICY TYPE  Response to consultation
DATE  2018-04-23
TOPICS  Health care and patient safety, Pharmaceuticals, prescribing, cannabis, drugs

Documents

Dear Dr. Keen:

The Canadian Medical Association (CMA) appreciates the opportunity to provide comments on the online public consultation on front-of-package labelling of cannabis and cannabis products. The CMA is sending this consultation on behalf of the Canadian Medical Association, the Canadian Nurses Association, and the Canadian Dental Association.

The CMA reiterates that the public health community has voiced concern about the front-of-package labelling of cannabis and cannabis products. While the CMA supports the intention to provide consumers with accurate information about the products, the CMA advises caution when it comes to the potential harms of labelling.

The CMA supports the concept of the proposed emphasis on the appeal and risk of the product, ensuring that the principal label is not too small. The CMA is concerned, however, with the potential for harm when this emphasis is placed on the package rather than the product. The CMA recommends that the emphasis on the package be balanced with the emphasis on the product to ensure that consumers are aware of the potential harms of cannabis and cannabis products.

Bill C-45: The Cannabis Act

CMA Policybase - Canadian Medical Association
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13861

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Parliamentary submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2018-04-18</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

Documents
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts
https://policybase.cma.ca/link/policy13918

POLICY TYPE       Parliamentary submission
DATE              2018-02-15
TOPICS            Pharmaceuticals, prescribing, cannabis, drugs
                  Health care and patient safety

Documents
Proposed approach to the regulation of cannabis
https://policybase.cma.ca/link/policy13838

POLICY TYPE
Response to consultation

DATE
2018-01-19

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Excise duty framework for cannabis products
https://policybase.cma.ca/link/policy13799

POLICY TYPE
Response to consultation

DATE
2017-12-07

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs